Ataxia-Telangiectasia Overview
Learn About Ataxia-Telangiectasia
Ataxia-telangiectasia is a rare childhood disease. It affects the brain and other parts of the body.
Ataxia refers to uncoordinated movements, such as walking. Telangiectasias are enlarged blood vessels (capillaries) just below the surface of the skin. Telangiectasias appear as tiny, red, spider-like blood vessels.
Louis-Bar syndrome
Ataxia-telangiectasia is inherited. This means it is passed down through families. It is an autosomal recessive trait. Both parents must provide a copy of a nonworking gene for the child to have symptoms of the disorder.
The disease results from a variant in the ATM gene. This gene provides instructions for making a protein that helps control the rate at which cells grow and divide. Defects in this gene can lead to abnormal cell death in many sites of the body, including the part of the brain that helps coordinate movement.
Boys and girls are equally affected.
Symptoms include:
- Decreased coordination of movements (ataxia) in late childhood that can include ataxic gait (cerebellar ataxia), jerky gait, unsteadiness
- Decreasing mental development, slows or stops after age 10 to 12
- Delayed walking
- Discoloration of skin areas exposed to sunlight
- Discoloration of skin (coffee-with-milk-colored spots)
- Enlarged blood vessels in skin of nose, ears, and inside of the elbow and knee
- Enlarged blood vessels in the whites of the eyes
- Jerky or abnormal eye movements (nystagmus) late in the disease
- Premature graying of the hair
- Seizures
- Sensitivity to radiation, including x-rays
- Severe respiratory infections that keep coming back (recurring)
There is no specific treatment for ataxia-telangiectasia. Treatment is directed at specific symptoms.
Mid-Atlantic Post Acute And Long Term Care PLLC
Robert Walters is a Geriatrics specialist and an Internal Medicine provider in Norfolk, Virginia. Dr. Walters and is rated as an Advanced provider by MediFind in the treatment of Ataxia-Telangiectasia. His top areas of expertise are End-Stage Renal Disease (ESRD), Ataxia-Telangiectasia, Anemia, and Stroke. Dr. Walters is currently accepting new patients.
Mcv Associated Physicians
Hashim Mann is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Mann and is rated as an Experienced provider by MediFind in the treatment of Ataxia-Telangiectasia. His top areas of expertise are Multiple Myeloma, Schnitzler Syndrome, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Mann is currently accepting new patients.
Mohammad Islam is a General Practice provider in Falls Church, Virginia. Dr. Islam and is rated as an Experienced provider by MediFind in the treatment of Ataxia-Telangiectasia. His top areas of expertise are Ataxia-Telangiectasia, Common Cold, Telangiectasia, and Heavy Metal Poisoning.
More information and support for people with ataxia-telangiectasia condition and their families can be found at:
- Ataxia Telangiectasia Children's Project: www.atcp.org
- National Ataxia Foundation (NAF): www.ataxia.org
Early death is common, but life expectancy varies.
Because people with this condition are very sensitive to radiation, they should never be given radiation therapy, and no unnecessary x-rays should be done.
Complications may include:
- Cancer, such as lymphoma
- Diabetes
- Kyphosis
- Progressive movement disorder that leads to wheelchair use
- Scoliosis
- Severe, recurrent lung infections
Contact your provider if your child develops symptoms of this disorder.
Couples with a family history of this condition who are considering pregnancy may consider genetic counseling.
Parents of a child with this disorder may have a slight increased risk for cancer. They should have genetic counseling and increased cancer screenings.
Summary: This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, whic...
Summary: This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Published Date: September 18, 2023
Published By: Anna C. Edens Hurst, MD, MS, Associate Professor in Medical Genetics, The University of Alabama at Birmingham, Birmingham, AL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Cunningham-Rundles C. Primary immunodeficiency diseases. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 231.
Martin KL. Vascular disorders. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 669.
National Center for Advancing Translational Sciences. Genetic and Rare Diseases Information Center website. Ataxia-telangiectasia. rarediseases.info.nih.gov/diseases/5862/ataxia-telangiectasia. Updated February 2023. Accessed October 17, 2023.
Safier RA, Cleves-Bayon C, Gaesser J. Neurology. In: Zitelli BJ, McIntire SC, Nowalk AJ, eds. Zitelli and Davis' Atlas of Pediatric Physical Diagnosis. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 16.